News
Insilico Medicine files third HKEX IPO attempt, as biotech develops rentosertib for IPF and other drugs with AI-driven ...
Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...
Lantheus finally came clean about the fate of its experimental radiopharmaceutical for prostate cancer, ...
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price up by as much as 35% premarket Friday.
Welcome back to Endpoints Weekly — thanks for starting your Saturday with us. It was a busy week in the biopharma world. FDA Commissioner Marty Makary … ...
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...
President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...
Brian Armstrong’s NewLimit raises a $130M Series B, laying out road map for anti-aging drugs
NewLimit raises $130M Series B led by Kleiner Perkins to advance epigenetic reprogramming research for liver disease ...
CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results